CD155, also called PVR, stands at a biologically interesting interface between tumor and immune cells. Among others, it interacts with the inhibitory immune receptor TIGIT and the activating receptor CD226. The spatial visualization of CD155 together with further immune cell markers can therefore be of particular interest for research projects on the TIGIT axis and the tumor microenvironment.
Where the project stands today
Jürgen Frerichs initiated the production of antibody clones against CD155. ONCOdianova has invested in this development. This production has yielded 17 CD155 candidate clones that are now available for the next scientific development phase.
In the next step the 17 clones are to be examined experimentally in stages. The aim is to identify suitable candidates and then to characterize them in more detail on selected control and tumor tissues.
In this way an early candidate can become a research reagent that can be used reproducibly for a clearly defined tissue-based application.
17 candidates for your CD155 project
CD155/PVR is an established research target for which various commercial antibodies are already available. The value of our pipeline programme therefore does not lie in simply offering another finished CD155 antibody, but in giving a research group access to 17 candidates for its own scientific evaluation and further development.
ONCOdianova has 17 CD155 candidate clones available for the next scientific development phase. An experienced research group, pathology laboratory or development partner can independently investigate, compare and further characterize one or more of these candidates.
The partner may evaluate the candidates under conditions relevant to its own research project — for example using human FFPE tissue, its own controls and an established IHC or multiplex platform. In this way, the scientific direction of further development can be substantially shaped by the research question and expertise of the participating partner.
ONCOdianova provides the agreed CD155 candidate clones and scientific exchange. Experimental testing, optimization and validation are carried out by the development partner at its own development risk and expense. This may include comparative screening of the clones, development of suitable experimental conditions, evaluation of control and tumour tissues and comparison with established research reagents.
The clones remain with ONCOdianova.
Scientific and commercial perspective
For the development partner, this creates the opportunity to build an independent scientific development project around an early candidate and to actively shape its further direction.
Scientific publication of suitable results is expressly encouraged. Authorship and scientific recognition will reflect the actual contribution of the participants and the rules of the respective scientific journal.
If the joint development work results in a scientifically and commercially successful clone, a success-based economic participation can be agreed before the collaboration begins. Depending on the contribution and the mutual agreement, this may relate to the respective clone, its further commercialization or revenues generated from it.
Further cooperation, participation or licensing models may also be agreed individually where appropriate for the specific project.
The scope and conditions of the collaboration, rights to the results, scientific publication, use of the materials provided and any potential economic participation will be agreed individually and in writing before the respective development phase begins.
Are you already working with CD155, TIGIT, the TIGIT axis or human FFPE tumour tissue and interested in scientifically evaluating one of the 17 CD155 candidates and actively contributing to its further development? We would be pleased to discuss the possibilities confidentially.
Early research and development project. The suitability of the 17 clones for the intended application is the subject of the planned scientific evaluation. For research use only.